HOPKINTON, Mass., Sept. 2 Caliper Life Sciences,Inc. (Nasdaq: CALP), a leading provider of tools and services for drugdiscovery and life sciences research, today announced that, as anticipated,researchers using the LabChip(R) EZ Reader(TM) platform for screening andprofiling kinase inhibitors now have access to more than 200 kinase assays.The assays are available in Caliper's ProfilerPro(TM) reagent format, apre-packaged, ready-to-use kit that enables in-house kinase profiling to beperformed in a single day.
Each of Caliper's ProfilerPro Kinase Selectivity Assay Kits contain allnecessary reagents and controls for rapidly profiling up to 12 differentcompounds against 24 protein kinases per kit; and now more than 200 kinasesare available in this format. All necessary reagents are pre-dispensed intoreaction-ready 384 well microtiter plates to simplify workflows and acceleratetime to results. ProfilerPro reagent kits are analyzed using proprietarymicrofluidic LabChip assay technology.
"Caliper's unique same-day kinase profiling platform enables researchersto make better compounds by providing chemists faster access to moreinformation about potential off target liabilities," said Rick Bunch, businessunit manager, LabChip Systems, Caliper Life Sciences. "The combination of highquality data generated by LabChip microfluidic assays with workflowimprovements inherent to ProfilerPro reagents means that overall drugdiscovery programs can be accelerated, enabling companies to bring drugs tomarket faster."
Caliper's EZ Reader series, a suite of instruments for screening andprofiling kinase inhibitors and performing kinetic mechanism-of-actionstudies, utilizes microfluidic separation and direct detection of bothsubstrates and products to generate high quality, reproducible data to qualifypotential lead candidates. Caliper provides researchers in oncology andinflammation therapeutic areas with platforms and services for targetvalidation; biochemical screening and profiling; cancer cell panels for drugcombinations, monotherapy and isogenic analysis; and in vivo efficacy studiesusing IVIS technology for subcutaneous, orthotropic, and metastatic tumormodels; and in vivo pharmacodynamic analysis.
Caliper also today separately announced the availability of RapidKinaseprofiling service from Caliper Discovery Alliances and Services (CDAS), thecompany's contract research organization. This service offering incorporatesCaliper's LabChip EZ Reader technology and ProfilerPro reagents. (Additionaldetails can be found in the press release "Caliper Life Sciences LaunchesRapidKinase(TM) Profiling Services and Mechanism of Action(TM) Studies."http://www.caliperls.com/about/news-media-center/press-releases/)
Caliper offers a broad portfolio of Lab Chip drug discovery and separationsystems. For additional information or to order the EZ Reader platform, pleasevisit: http://www.caliperls.com/products/labchip-systems/.
About Caliper Life Sciences
Caliper Life Sciences is a premier provider of cutting-edge technologiesenabling researchers in the life sciences industry to create life-saving andenhancing medicines and diagnostic tests more quickly and efficiently.Caliper is aggressively innovating new technology to bridge the gap between invitro assays and in vivo results and then translating those results into curesfor human disease. Caliper's portfolio of offerings includes state-of-the-artmicrofluidics, lab automation & liquid handling, optical imaging technologies,and discovery & development outsourcing solutions. For more information pleasevisit www.caliperLS.com.
Caliper, LabChip, EZ Reader, ProfilerPro, RapidKinase and Mechanism ofAction are trademarks of Caliper Life Sciences, Inc.
SOURCE Caliper Life Sciences, Inc.